Norges Bank’s Checkpoint Therapeutics CKPT Stock Holding History

Norges Bank’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-26,850	Closed	-$475K	–	2078
2022 Q1	$475K	Hold	26,850	–	–	﹤0.01%	2104
2021 Q4	$835K	Buy	+26,850	New	+$889K	﹤0.01%	2122

Other funds holding CKPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Norges Bank's CKPT Position: Q2 2022 in Review

Norges Bank sold out of Checkpoint Therapeutics (CKPT) in Q2 2022, closing a stake of 26,850 shares — an estimated $475K sold.

Norges Bank first reported a position in CKPT in Q4 2021 and held it in 2 quarters. The position peaked at $835K in Q4 2021. 62 funds tracked by Wall St. Rank hold CKPT as of Q2 2022.

Norges Bank reported no remaining Checkpoint Therapeutics position as of Q2 2022 after selling out during the quarter.
Norges Bank sold 26,850 Checkpoint Therapeutics shares in Q2 2022, an estimated $475K.
Norges Bank first reported a position in Checkpoint Therapeutics in Q4 2021 and held it in 2 quarters.
Norges Bank's Checkpoint Therapeutics position peaked at $835K in Q4 2021.
62 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.